Health
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 – - Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds - ROCKVILLE, Md
About this update from Theriva Biologics, Inc.
[{"type":"image","alt":"Theriva Biologics, Inc.","displaySize":"","headline":null,"caption":"Theriva Biologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NwCW1pyw7ahIW1qecrDFNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/66da9d5d384dea69bc442e7797b7b48a","width":300,"height":102}},"lazy":false},{"type":"text","content":"- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 –","length":272,"tagName":"p"},{"type":"text","content":"- Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds -","length":213,"tagName":"p"},{"type":"text","content":"ROCKVILLE, Md. and BARCELONA, Spain, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced an invited presentation of clinical outcomes and safety data from the investigator sponsored Phase 1 clinical study (NCT03284268) evaluating the safety and tolerability of two intravitreal injections of VCN-01 (zabilugene almadenorepvec) in pediatric patients with intraocular retinoblastoma that was refractory to systemic, intra-arterial, or intravitreal chemotherapy, and for whom enucleation was the only recommended treatment. Preclinical data describing the synergistic antitumor effects observed when topotecan (a standard of care chemotherapy for retinoblastoma) is coadministered with VCN-01 will also be presented. These data will be presented during a retinoblastoma focused session at the upcoming Asia-Pacific Academy of Ophthalmology (APAO) Congress (held in conjunction with the 37th Annual Scientific Meeting Hong Kong Ophthalmological Symposium) taking place in Hong Kong, China, 5-8 February 2026.","length":1210,"tagName"...